3.02

2.27% -0.07

After Hours: 3.03 0.010 +0.33%

Elicio Therapeutics Inc (ELTX)

Overview News Price History Discussions Forecast

Elicio Therapeutics Inc stock is traded at $3.02, with a volume of 253.18K. It is down -2.27% in the last 24 hours and down -2.89% over the past month. Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Previous Close:

$3.09

Open:

$3.05

24h Volume:

253.18K

Relative Volume:

0.16

Market Cap:

$79.37M

Revenue:

Net Income/Loss:

$-40.19M

P/E Ratio:

-1.2882

EPS:

-2.3444

Net Cash Flow:

$-38.49M

1W Performance:

-2.58%

1M Performance:

-2.89%

6M Performance:

-64.84%

1Y Performance:

-69.31%

1-Day Range:

$3.00

$3.085

1-Week Range:

$3.00

$3.205

52-Week Range:

$2.66

$16.00

Elicio Therapeutics Inc Stock (ELTX) Company Profile

Name

Elicio Therapeutics Inc

Sector

Healthcare (1082)

Industry

Biotechnology (606)

Phone

(857) 209-0050

Address

451 D STREET, 5TH FLOOR, BOSTON

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

ELTX's Discussions on Twitter

Compare ELTX vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ELTX Elicio Therapeutics Inc	3.02	81.21M	0	-40.19M	-38.49M	-2.3444
VRTX Vertex Pharmaceuticals Inc	515.55	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	805.93	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	987.84	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	212.00	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.51	39.31B	5.76B	514.49M	1.10B	4.4813

Elicio Therapeutics Inc Stock (ELTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-15-26	Initiated	Ladenburg Thalmann	Buy
Mar-10-26	Initiated	Rodman & Renshaw	Buy

Elicio Therapeutics Inc Stock (ELTX) Latest News

Aug 15, 2026

ELTX Stock Heads For Worst Day Ever — Elicio Therapeutics' Pancreatic Cancer Data Disappoints - Stocktwits

Aug 15, 2026

Elicio Therapeutics (NASDAQ:ELTX) Stock Rating Upgraded by Wall Street Zen - MarketBeat

Aug 15, 2026

Aug 14, 2026

Elicio Therapeutics (ELTX) Stock Forum and Discussion - Moomoo

Aug 14, 2026

Aug 13, 2026

Elicio Therapeutics: Q2 Earnings Snapshot - AOL.com

Aug 13, 2026

Elicio Therapeutics Q2 Results: EPS beats estimate, losses narrow 35% YoY - scanx.trade

Aug 13, 2026

Elicio Therapeutics (NASDAQ:ELTX) Announces Earnings Results - MarketBeat

Aug 13, 2026

Elicio Therapeutics (ELTX) faces going-concern risk after $20M loss and trial miss - Stock Titan

Aug 13, 2026

Elicio Therapeutics Q2 net loss narrows as R&D expenses fall - TradingView

Aug 13, 2026

Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - The Manila Times

Aug 13, 2026

Elicio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 13, 2026

Aug 11, 2026

KLRS Stock Price and Chart — NASDAQ:KLRS - TradingView

Aug 11, 2026

Aug 10, 2026

Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma - The Manila Times

Aug 10, 2026

Elicio Therapeutics Announces Opening of MSK-Led Phase 1 Neoadjuvant Study of ELI-002 7P in Resectable Pancreatic Cancer - Quiver Quantitative

Aug 10, 2026

Elicio Therapeutics Announces Activation of the - GlobeNewswire

Aug 10, 2026

Aug 06, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review

Aug 06, 2026

ELTX Q2'26 Earnings: EPS estimate is (0.54) USD - TradingView

Aug 06, 2026

(ELTX) Volatility Zones as Tactical Triggers - Stock Traders Daily

Aug 06, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review

Aug 06, 2026

Aug 05, 2026

Certain Stock Options of Elicio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-AUG-2026. - marketscreener.com

Aug 05, 2026

Certain Warrants of Elicio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-AUG-2026. - marketscreener.com

Aug 05, 2026

Aug 03, 2026

Elicio Therapeutics Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView

Aug 03, 2026

Jul 31, 2026

ELTX Q2'26 Earnings: revenue estimate is 0 USD - TradingView

Jul 31, 2026

Jul 30, 2026

Elicio Therapeutics (ELTX) Expected to Post Earnings on Thursday - MarketBeat

Jul 30, 2026

Jul 29, 2026

Elicio Therapeutics (NASDAQ:ELTX) Stock Price Down 1.7%Here's What Happened - MarketBeat

Jul 29, 2026

Jul 28, 2026